1Dhooge CR, De Moerloose BM, Benoit YC,et al. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma.Cancer, 1997,80 ( 7 ) : 1250.
2Chen H, Haddad G, Thomer PS , et al. Pglycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med,1991,325:1608.
3Matsunaga T, Shirasawa H, Hishiki T, et al.Expression of MRP and cMOAT in childhood neuroblastoma and malignant liver tumors and its relevance to clinical behavior. Jpn J Cancer Res,1998,89:1276.
4Haber M, Bordow SB, Gilbert J, et al. Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells. Oncogene, 1999,18:2777.
5Norris MD, Bordow SB, Marshall GM, et al.Expression of the gene for muhidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med,1996,334:231.
6Izquierdo MA, Neefjes JJ, Mathari AEL, et al. Overexpression of the ABC transporter TAP in muhidrug-resistant human cancer cell lines. Br J Cancer, 1996,74 : 1961.
7List A, Spier C, Grogan T, et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood,1996,87:2463.
8Yasuno T, Matsumuza T, Shikata T, et al.Establishment and characterization of a cisplatin-resistant human neuroblastoma cell line. Anticancer Res,1999,19(5B) :4049.
9Kurokawa H, Ishida T, Nishio K, et al. γ-Glutatmylcysteine synthetase gene overex-pression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance, Biochem Biophys Res Commun. 1995.216:258.
10Keshelava N, Zuo JJ, Waidyaratne NS, et al. p53 mutations and loss of p53 function confer muhidrug resistance in neuroblastoma. Med Pediatr Oncol,2000,35:563.
